Clinical Trials Logo

Triple Negative Breast Neoplasms clinical trials

View clinical trials related to Triple Negative Breast Neoplasms.

Filter by:

NCT ID: NCT06328465 Recruiting - Clinical trials for Triple Negative Breast Cancer

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

fREEDOM
Start date: November 22, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment. The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI.

NCT ID: NCT06324240 Not yet recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating patients with triple negative breast cancer. This vaccine is made by taking a piece of patient's triple negative breast cancer to design a vaccine to stimulate the immune system's memory. Patients are treated with the personalized vaccine immunotherapy with or without monoclonal antibodies, such as pembrolizumab and ipilimumab. This approach may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving personalized TMV vaccine with pembrolizumab or ipilimumab may help the immune system attack cancer better and reduce the risk of this breast cancer coming back or growing.

NCT ID: NCT06318897 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Start date: September 30, 2024
Phase: Phase 2
Study type: Interventional

To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.

NCT ID: NCT06318507 Recruiting - Breast Neoplasms Clinical Trials

The Intestinal Microbiome in Triple Negative Breast Cancer Treated With Immunotherapy

IMPACT
Start date: March 11, 2024
Phase:
Study type: Observational

This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.

NCT ID: NCT06309459 Completed - Clinical trials for Triple Negative Breast Cancer

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Start date: August 1, 2018
Phase:
Study type: Observational

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

NCT ID: NCT06299163 Recruiting - Endometrial Cancer Clinical Trials

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Start date: March 29, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

NCT ID: NCT06291064 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

TARMAC
Start date: June 2024
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.

NCT ID: NCT06281210 Recruiting - Breast Cancer Clinical Trials

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

BETTY-CRASY
Start date: December 11, 2023
Phase: N/A
Study type: Interventional

This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT.

NCT ID: NCT06279364 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Start date: February 2024
Phase: Phase 3
Study type: Interventional

The aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 positive tumors who received prior anti-programmed cell death 1 (PD-1)/PD-L1 inhibitor in early setting

NCT ID: NCT06273852 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Start date: March 2024
Phase: Early Phase 1
Study type: Interventional

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.